BR112016012528A2 - composto imunogênico - Google Patents
composto imunogênicoInfo
- Publication number
- BR112016012528A2 BR112016012528A2 BR112016012528A BR112016012528A BR112016012528A2 BR 112016012528 A2 BR112016012528 A2 BR 112016012528A2 BR 112016012528 A BR112016012528 A BR 112016012528A BR 112016012528 A BR112016012528 A BR 112016012528A BR 112016012528 A2 BR112016012528 A2 BR 112016012528A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- moiety
- amino acid
- physicochemical properties
- immunostimulatory
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229960001438 immunostimulant agent Drugs 0.000 abstract 2
- 239000003022 immunostimulating agent Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1321242.8A GB201321242D0 (en) | 2013-12-02 | 2013-12-02 | Immunogenic compound |
| PCT/GB2014/053577 WO2015082905A1 (en) | 2013-12-02 | 2014-12-02 | Immunogenic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016012528A2 true BR112016012528A2 (pt) | 2017-09-26 |
Family
ID=49979653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016012528A BR112016012528A2 (pt) | 2013-12-02 | 2014-12-02 | composto imunogênico |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9962453B2 (https=) |
| EP (1) | EP3077052A1 (https=) |
| JP (2) | JP6792452B2 (https=) |
| KR (1) | KR102356869B1 (https=) |
| CN (1) | CN105873638A (https=) |
| BR (1) | BR112016012528A2 (https=) |
| CA (1) | CA2931933A1 (https=) |
| EA (1) | EA201691146A1 (https=) |
| GB (1) | GB201321242D0 (https=) |
| WO (1) | WO2015082905A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| GB201321242D0 (en) * | 2013-12-02 | 2014-01-15 | Immune Targeting Systems Its Ltd | Immunogenic compound |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| US11464854B2 (en) * | 2017-03-23 | 2022-10-11 | Children's Medical Center Corporation | Methods and compositions relating to adjuvants |
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| ES2951817T3 (es) | 2017-08-22 | 2023-10-25 | Dynavax Tech Corp | Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos |
| US10722591B2 (en) | 2017-11-14 | 2020-07-28 | Dynavax Technologies Corporation | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof |
| KR20250078621A (ko) * | 2018-07-10 | 2025-06-02 | 세퀴러스 피티와이 리미티드 | 응집체의 제거 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2020205996A2 (en) * | 2019-04-01 | 2020-10-08 | Altimmune Uk Ltd | Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses |
| WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
| US20250360205A1 (en) * | 2022-06-09 | 2025-11-27 | Academia Sinica | Nod1 modulators and uses thereof |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
| KR102784104B1 (ko) * | 2024-04-04 | 2025-03-24 | 대한민국(방위사업청장) | 이미퀴모드 및 Nod2 수용체 자극 성분 또는 박테리아를 포함하는 면역 어쥬번트 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5294605A (en) | 1990-07-19 | 1994-03-15 | The Scripps Research Institute | Amphiphilic peptide compositions and analogues thereof |
| FR2744123B1 (fr) * | 1996-01-26 | 1998-04-17 | Carelli Claude Marcel Henri | Molecules biologiquement actives plus particulierement peptidiques ayant un effet potentialisateur de l'activite biologique de l'hormone de croissance |
| ES2312659T3 (es) | 2001-11-29 | 2009-03-01 | 3M Innovative Properties Company | Formulaciones farmaceuticas que comprenden un modificador de la respuesta inmune. |
| DK1545597T3 (da) | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
| CA2545825A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
| CA2605808A1 (en) | 2005-04-25 | 2006-11-02 | 3M Innovative Properties Company | Immunostimulatory compositions |
| CN101790380B (zh) | 2007-02-07 | 2013-07-10 | 加利福尼亚大学董事会 | 合成tlr激动剂的缀合物及其应用 |
| ES2532896T5 (es) * | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| TR201802083T4 (tr) | 2008-10-24 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Lipidatlı imidazokinolin türevleri. |
| EP2387421A1 (en) * | 2009-01-14 | 2011-11-23 | SKU Asset Management GmbH | Compounds comprising n-formyl-methionine residues and tumor-targeting peptides |
| JP2013512859A (ja) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン |
| US8916162B2 (en) | 2010-02-20 | 2014-12-23 | Alexey Gennadievich Zdanovsky | Botulinum neurotoxin antigenic compositions and methods |
| US9242980B2 (en) | 2010-08-17 | 2016-01-26 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
| GB201022147D0 (en) * | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| WO2012113413A1 (en) * | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| JP6460789B2 (ja) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体 |
| GB201321242D0 (en) * | 2013-12-02 | 2014-01-15 | Immune Targeting Systems Its Ltd | Immunogenic compound |
-
2013
- 2013-12-02 GB GBGB1321242.8A patent/GB201321242D0/en not_active Ceased
-
2014
- 2014-12-02 KR KR1020167017734A patent/KR102356869B1/ko not_active Expired - Fee Related
- 2014-12-02 JP JP2016555933A patent/JP6792452B2/ja not_active Expired - Fee Related
- 2014-12-02 US US15/100,800 patent/US9962453B2/en active Active
- 2014-12-02 WO PCT/GB2014/053577 patent/WO2015082905A1/en not_active Ceased
- 2014-12-02 CN CN201480071742.1A patent/CN105873638A/zh active Pending
- 2014-12-02 CA CA2931933A patent/CA2931933A1/en active Pending
- 2014-12-02 EP EP14809960.9A patent/EP3077052A1/en not_active Withdrawn
- 2014-12-02 BR BR112016012528A patent/BR112016012528A2/pt not_active IP Right Cessation
- 2014-12-02 EA EA201691146A patent/EA201691146A1/ru unknown
-
2018
- 2018-05-02 US US15/968,839 patent/US10434183B2/en not_active Expired - Fee Related
-
2019
- 2019-10-07 US US16/595,311 patent/US10849984B2/en not_active Expired - Fee Related
-
2020
- 2020-11-06 US US17/091,106 patent/US20210145975A1/en not_active Abandoned
- 2020-11-06 JP JP2020185572A patent/JP7095053B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20190125889A1 (en) | 2019-05-02 |
| WO2015082905A1 (en) | 2015-06-11 |
| US9962453B2 (en) | 2018-05-08 |
| GB201321242D0 (en) | 2014-01-15 |
| JP6792452B2 (ja) | 2020-11-25 |
| US20200038519A1 (en) | 2020-02-06 |
| US10849984B2 (en) | 2020-12-01 |
| US10434183B2 (en) | 2019-10-08 |
| US20210145975A1 (en) | 2021-05-20 |
| US20160310603A1 (en) | 2016-10-27 |
| JP2021020967A (ja) | 2021-02-18 |
| JP7095053B2 (ja) | 2022-07-04 |
| EA201691146A1 (ru) | 2016-12-30 |
| KR102356869B1 (ko) | 2022-01-27 |
| JP2016540050A (ja) | 2016-12-22 |
| EP3077052A1 (en) | 2016-10-12 |
| KR20160113104A (ko) | 2016-09-28 |
| CN105873638A (zh) | 2016-08-17 |
| CA2931933A1 (en) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016012528A2 (pt) | composto imunogênico | |
| CO2018000303A2 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| CY1121868T1 (el) | Πεπτιδια και νανοσωματιδια για ενδοκυτταρικη διανομη μοριων | |
| BR112018075259A2 (pt) | composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0 | |
| BR112015030229A2 (pt) | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado | |
| UA116004C2 (uk) | Фармацевтична композиція з покращеною біодоступністю | |
| CR20160229A (es) | Inhibidires de bromodominio | |
| BR112017009277A2 (pt) | compostos de silicone | |
| MX2018001990A (es) | Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac. | |
| BR112017009405A2 (pt) | composições antibióticas. | |
| MX380798B (es) | Profármacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| BR112018007395A2 (pt) | 2,4-di-hidróxi-nicotinamidas como agonistas de apj | |
| WO2015198240A3 (en) | Compositions and methods for long acting proteins | |
| BR112017025728A2 (pt) | fragmentos mutantes da proteína ras | |
| BR112018004644A2 (pt) | processo para alisamento semipermanente e modelagem permanente do cabelo | |
| CY1118561T1 (el) | Λυοφιλιωμενη φαρμακοτεχνικη μορφη αριπιπραζολης | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| EA201791537A1 (ru) | Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение | |
| MX2016011394A (es) | Moleculas de andamiaje a base de fibronectina estabilizada. | |
| NZ710602A (en) | Methods for reducing pyrogenicity in a seaweed extract | |
| BR112017025639A2 (pt) | brinquedo de transformação | |
| EA201591678A1 (ru) | Антиперспирантные композиции | |
| BR112017002926A2 (pt) | composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivo | |
| DOP2019000047A (es) | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres | |
| PH12017502319A1 (en) | Injectable pharmaceutical formulations of lefamulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61P 35/00 (2006.01), A61P 37/04 (2006.01), A61K 4 |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |